Novartis Stock - FDA advisory panel backs remibrutinib data ahead of MS submission
22.06.2026 - 04:57:54 | ad-hoc-news.de
Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 04:57 CET. Details in the imprint.
Novartis (CH0012005267) is drawing investor attention after positive expert feedback on pivotal data for its BTK inhibitor remibrutinib in multiple sclerosis was discussed with the US Food and Drug Administration, as reported by Reuters. This comes as the company prepares its next wave of filings in neurology and immunology.
All news and analysis on Novartis stock
Key updates on the Novartis pipeline, earnings and regulatory milestones are compiled here for investors following the Swiss pharma group.
What Reuters reports on remibrutinib
According to a detailed Reuters report, US experts reviewing Novartis data signaled support for the efficacy and safety profile of remibrutinib in relapsing multiple sclerosis. The discussion focused on phase 3 trial results and potential labeling questions.
Remibrutinib is one of several BTK inhibitors racing to market in MS, an area where Novartis already sells Gilenya and Kesimpta. The company has indicated that, subject to regulatory interactions, it aims to file remibrutinib in major markets in the near term.
Weekly outlook for Novartis investors
This week, investors will watch for any follow-up disclosures on the FDA dialogue and clarity on the expected timing of the US and EU submissions for remibrutinib. Pipeline milestones have become a core driver of sentiment for large-cap pharma stocks.
On the calendar side, Novartis has already guided that its next major scheduled event is second-quarter earnings, expected in late July based on the company’s published financial calendar. The focus remains on margins, cash generation and capital allocation policy.
How the company makes money
Novartis generates most of its revenue from innovative prescription medicines in areas such as oncology, cardiovascular, immunology and neuroscience. Key products include heart-failure drug Entresto, psoriasis and psoriatic arthritis treatment Cosentyx and the multiple sclerosis therapy Kesimpta.
Where the stock trades today
Novartis shares (CH0012005267) trade on SIX Swiss Exchange at CHF 94.20 as of 06/21/2026, 17:30 CET.
Key facts on Novartis stock
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Ticker: NOVN
- Venue: SIX Swiss Exchange
- Price (as of 06/21/2026, 17:30 CET): 94.20 CHF
- Market cap: 197,500,000,000 CHF (as of 06/21/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI, Stoxx Europe 50
- Next earnings date: 07/23/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
